Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes

Abstract

This study aimed to investigate the effects on a possible improvement in aerobic and anaerobic performance of oral terbutaline (TER) at a supra-therapeutic dose in 7 healthy competitive male athletes. On day 1, ventilatory threshold, maximum oxygen uptake [Formula: see text] and corresponding power output were measured and used to determine the exercise load on days 2 and 3. On days 2 and 3, 8mg of TER or placebo were orally administered in a double-blind process to athletes who rested for 3h, and then performed a battery of tests including a force-velocity exercise test, running sprint and a maximal endurance cycling test at Δ50% (50% between VT and [Formula: see text]). Lactatemia, anaerobic parameters and endurance performance ([Formula: see text] and time until exhaustion) were raised during the corresponding tests. We found that TER administration did not improve any of the parameters of aerobic performance (p>0.05). In addition, no change in [Formula: see text] kinetic parameters was found with TER compared to placebo (p>0.05). Moreover, no enhancement of the force-velocity relationship was observed during sprint exercises after TER intake (p>0.05) and, on the contrary, maximal strength decreased significantly after TER intake (p<0.05) but maximal power remained unchanged (p>0.05). In conclusion, oral acute administration of TER at a supra-therapeutic dose seems to be without any relevant ergogenic effect on anaerobic and aerobic performances in healthy athletes. However, all participants experienced adverse side effects such as tremors.